Vasoconstriction to Endogenous Endothelin-1 Is Increased in the Peripheral Circulation of Patients With Essential Hypertension
- 19 October 1999
- journal article
- other
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (16) , 1680-1683
- https://doi.org/10.1161/01.cir.100.16.1680
Abstract
Background —In humans, endothelin (ET)-1 could be implicated in the pathophysiology of several cardiovascular diseases, including essential hypertension. We therefore evaluated the role of ET-1 in control of vascular tone in essential hypertension. Methods and Results —We used strain-gauge venous plethysmography to test changes in forearm blood flow induced by intrabrachial infusion of TAK-044 (10, 30, and 100 μg · 100 mL −1 · min −1 ), an ET A /ET B receptor antagonist, or sodium nitroprusside (1 and 2 μg · 100 mL −1 · min −1 ), a vasodilator that acts on smooth muscle cells, in hypertensive patients and healthy controls (n=10 in each group). The NO pathway was also evaluated by infusion of N G -monomethyl- l -arginine, (L-NMMA; 10, 30, and 100 μg · 100 mL −1 · min −1 ), an NO synthase inhibitor, and norepinephrine (3, 9, and 30 ng · 100 mL −1 · min −1 ) as control. Immunoreactive plasma ET-1 was measured by radioimmunoassay. In hypertensive patients, TAK-044 caused a vasodilation that was significantly ( P P r =−0.56, P Conclusions —These results indicate that TAK-044 caused a greater degree of vasodilation in the forearm vessels of essential hypertensive patients compared with normotensive subjects, an alteration associated with decreased tonic NO release.Keywords
This publication has 10 references indexed in Scilit:
- Endothelin as a regulator of cardiovascular function in health and diseaseJournal Of Hypertension, 1998
- The Effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential HypertensionNew England Journal of Medicine, 1998
- The peptide endothelin receptor antagonist, TAK‐044, produces sustained inhibition of endothelin‐1 mediated arteriolar vasoconstrictionBritish Journal of Clinical Pharmacology, 1997
- Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in ratsBritish Journal of Pharmacology, 1995
- Effect of local intra-arterial NG-monomethyl-L-arginine in patients with hypertensionJournal Of Hypertension, 1992
- Cloning and expression of a cDNA encoding an endothelin receptorNature, 1990
- A sensitive radioimmunoassay measuring endothelin-like immunoreactivity in human plasma: Comparison of levels in patients with essential hypertension and normotensive control subjectsClinical Science, 1990
- PLASMA ENDOTHELIN LEVELS IN PATIENTS WITH URAEMIAThe Lancet, 1989
- A specific inhibitor of nitric oxide formation from l‐arginine attenuates endothelium‐dependent relaxationBritish Journal of Pharmacology, 1989
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988